Document Detail


The Histone Deacetylase Inhibitor Trichostatin A Synergistically Resensitizes a Cisplatin Resistant Human Bladder Cancer Cell Line.
MedLine Citation:
PMID:  21255805     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
PURPOSE:: Cisplatin is the mainstay of treatment for advanced bladder cancer. However, intrinsic or acquired resistance to cisplatin is common, which severely limits its therapeutic potential. We determined the synergistic antitumor effect of cisplatin and the histone deacetylase inhibitor trichostatin A in cisplatin resistant human bladder cancer cells. MATERIALS AND METHODS:: The cisplatin resistant human bladder cancer cell line T24R2 was exposed to cisplatin and/or trichostatin A. Tumor cell proliferation was examined by cell counting kit assay. Synergism between 2 drugs was examined by the combination index. Changes in cell cycle and apoptosis were determined by flow cytometry. We analyzed the expression of caspase-3, 8 and 9, poly(adenosine diphosphate-ribose) polymerase, p21(WAF1/CIP1), cyclin A, B1 and D1, Cdc2c, p-Cdc2c, Cdc25c, p-Cdc25c, cytochrome c, p-Akt, t-Akt, Bcl-2, Bax, Bad, vascular endothelial growth factor and fetal liver kinase-1 by Western blot and colorimetric assay. RESULTS:: Based on the combination index and isobole analysis of the Cell Counting Kit-8 assay we observed a strong synergistic antitumor effect between cisplatin and trichostatin A, allowing a 3.5 and 4.9-fold dose reduction in cisplatin and trichostatin A, respectively, while achieving an estimated 90% kill of T24R2 cells. The underlying mechanism could be synergistic cell cycle arrest, induction of caspase mediated apoptosis or up-regulated expression of pro-apoptotic Bad and Bax. CONCLUSIONS:: Results indicate that trichostatin A may synergistically enhance the antitumor effect of cisplatin and resensitize cisplatin resistant bladder cancer cells. These findings suggest the potential use of histone deacetylase inhibitor as a combination agent to enhance the antitumor effect of cisplatin in patients with advanced bladder cancer.
Authors:
Cheol Yong Yoon; Mi Jung Park; Jung Sun Lee; Sang Chul Lee; Jong Jin Oh; Hongzoo Park; Chang Wook Chung; Murod M Abdullajanov; Seong Jin Jeong; Sung Kyu Hong; Seok Soo Byun; Eun Sik Lee; Sang Eun Lee
Related Documents :
21325635 - Overexpressed pak4 promotes proliferation, migration and invasion of choriocarcinoma.
20485275 - The dual nature of t(h)17 cells: shifting the focus to function.
21294125 - The expression of cxcr4, cxcl12 and cxcr7 in malignant pleural mesothelioma.
21284385 - Antitumor agents. 284. new desmosdumotin b analogues with bicyclic b-ring as cytotoxic ...
19276355 - Nadph oxidase 4 contributes to transformation phenotype of melanoma cells by regulating...
11606725 - Endostatin regulates branching morphogenesis of renal epithelial cells and ureteric bud.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-1-20
Journal Detail:
Title:  The Journal of urology     Volume:  -     ISSN:  1527-3792     ISO Abbreviation:  -     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2011-1-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0376374     Medline TA:  J Urol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  MicroRNA-100 Expression is Independently Related to Biochemical Recurrence of Prostate Cancer.
Next Document:  Modified Scrotal (Bianchi) Mid Raphe Single Incision Orchiopexy for Low Palpable Undescended Testis:...